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Abstract
Objectives—To describe the differences in goals for their usual practice for various medical 
therapies from a number of international centers for children with severe traumatic brain injury.
Design—A survey of the goals from representatives of the international centers.
Setting—Thirty-two pediatric traumatic brain injury centers in the United States, United 
Kingdom, France, and Spain.
Patients—None.
Interventions—None.
Measurements and Main Results—A survey instrument was developed that required free-
form responses from the centers regarding their usual practice goals for topics of intracranial 
hypertension therapies, hypoxia/ischemia prevention and detection, and metabolic support. 
Copyright © 2013 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care 
Societies
For information regarding this article, bellmj4@upmc.edu. 
The remaining authors have disclosed that they do not have any potential conflicts of interest.
HHS Public Access
Author manuscript
Pediatr Crit Care Med. Author manuscript; available in PMC 2015 June 04.
Published in final edited form as:
Pediatr Crit Care Med. 2013 October ; 14(8): 811–818. doi:10.1097/PCC.0b013e3182975e2f.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Cerebrospinal fluid diversion strategies varied both across centers and within centers, with roughly 
equal proportion of centers adopting a strategy of continuous cerebrospinal fluid diversion and a 
strategy of no cerebrospinal fluid diversion. Use of mannitol and hypertonic saline for 
hyperosmolar therapies was widespread among centers (90.1% and 96.9%, respectively). Of 
centers using hypertonic saline, 3% saline preparations were the most common but many other 
concentrations were in common use. Routine hyperventilation was not reported as a standard goal 
and 31.3% of centers currently use Pbo2 monitoring for cerebral hypoxia. The time to start 
nutritional support and glucose administration varied widely, with nutritional support beginning 
before 96 hours and glucose administration being started earlier in most centers.
Conclusions—There were marked differences in medical goals for children with severe 
traumatic brain injury across our international consortium, and these differences seemed to be 
greatest in areas with the weakest evidence in the literature. Future studies that determine the 
superiority of the various medical therapies outlined within our survey would be a significant 
advance for the pediatric neurotrauma field and may lead to new standards of care and improved 
study designs for clinical trials.
Keywords
cerebral hypoperfusion; hypoxia; intracranial hypertension; pediatric neurocritical care; pediatric 
traumatic brain injury; secondary Injuries
Over the past decade, a number of international efforts have been made to improve the care 
and outcomes of children with severe traumatic brain injury (TBI)—the leading cause of 
death of children and responsible for billions of dollars of medical and societal costs each 
year (1–6). In 2003, the first edition of the Guidelines for the Medical Management of 
Traumatic Brain Injury in Infants, Children and Adolescents was published (7), which 
included evidence-based recommendations along with expert opinions. This landmark work 
was updated in 2012, with slight modifications of the topics reviewed and a diminished 
emphasis on expert opinion (8). Although influential, these guidelines emphasize that the 
neurotrauma literature is insufficient to provide firm recommendations regarding a host of 
medical decisions (Table 1) that are important in caring for children with severe TBI—
including the superiority/inferiority of cerebrospinal fluid (CSF) diversion strategies, the 
relative effectiveness of various hyperosmolar therapies, the ability of hypoxia/ischemia 
monitoring strategies to improve outcomes, the timing and quantity of nutritional support, 
and the decisions on glucose administration and management. All of these decisions are 
likely to have some effect on overall outcomes, yet the current literature cannot discern their 
relative importance or impact on the overall outcomes.
During this time span, randomized controlled trials (RCTs) have failed to provide more 
substantive evidence for the guidelines. The Canadian Critical Care Trials Group and the 
Pediatric Traumatic Brain Injury Consortium: Hypothermia carried out a total of three 
studies to determine the efficacy of therapeutic hypothermia in children with severe TBI (9, 
10)—all of which failed to demonstrate efficacy. Significant variability in medical goals 
between centers has been suggested as a reason for the failure of these trials, and this pattern 
was previously observed in an RCT of hypothermia for adult TBI victims (11). For example, 
the use of hypertonic saline for intracranial hypertension was significantly greater in 
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children randomized to normothermia in the Hyp-HIT study—potentially introducing a bias 
into the study that was uncontrollable by the study investigators.
We hypothesize substantial variations in medical goals for children with severe TBI in the 
overall pediatric neurotrauma community and have performed a survey of these goals for 
this article. We speculate that these variations may play a role in differences in outcomes 
observed between centers in routine care as well as in clinical studies. We assembled an 
international consortium of clinical centers that also agreed to participate in a planned 
comparative effectiveness study of medical therapies for pediatric TBI.
METHODS
This study was submitted to the Institutional Review Board (IRB) of the University of 
Pittsburgh for their consideration and deemed to be exempt from IRB review. An 
international consortium of pediatric TBI participants was recruited from a variety of 
sources (members of the recently formed Pediatric Neurocritical Care Research Group 
[http://www.pncrg.org], site principal investigators from the “Cool Kids” Trial and the Hyp-
HIT study, and investigators within the ESPNIC [European Society of Pediatric and 
Neonatal Intensive Care] Neurocritical Care section). All potential participants were asked 
to report on the usual practices employed at their institution.
A survey instrument to determine current practices regarding intracranial hypertension 
therapies, hypoxia/ischemia monitoring strategies, and metabolic issues was generated 
(Table 2). In order to estimate how many children the participating institutions cared for 
with severe TBI—and therefore, to approximate the relative value of the survey—
respondents were asked to audit the number of cases of severe TBI their institution had 
admitted in the past 3 years. For this audit, inclusion criteria (age ≤ 18 yr, severe TBI with 
Glasgow Coma Scale score ≤ 8, and placement of intracranial pressure [ICP] monitor) and 
exclusion criteria (pregnancy, penetrating injury, and unknown mechanism) were applied. 
Respondents were asked to describe the goals for the usual practices that occur at their 
centers regarding the questions listed in Table 2. These answers were given in free form and 
respondents were free to explain their practices without interpretation and did not represent 
any form of medical record review. We chose the topics for the survey for a number of 
reasons. All of the topics were aspects of the most recent version of the pediatric TBI 
guidelines—with the requisite requirement that the topics within the guideline were deemed 
to be important in TBI outcomes. We were primarily considering medical therapies that 
were necessary for routine care of all children with severe TBI and tailored our inquiries to 
those topics. We considered inquiring about sedation and neuromuscular blockade usage 
within the survey, but felt that the existing literature demonstrating the relationship between 
these agents and outcomes was still extremely preliminary. Large intracenter variation was 
likely for these agents, making the information provided by the participants less reliable than 
those for the other topics. Similarly, we did not study antiseizure prophylaxis due to lack of 
evidence that it may change overall outcomes. For other topics, particularly corticosteroids 
and hypothermia, sufficient data exist within the literature to generate substantive 
recommendations, and therefore, these topics were not surveyed. Lastly, we did not study 
neurological imaging and decompressive surgery, as these are not medical therapies for 
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pediatric TBI. Results were collated and reported for the 18 different questions. Responses 
were analyzed overall and stratified based on institution size and location (United States vs 
international center).
RESULTS
A total of 32 centers were recruited from the United States, United Kingdom, Spain, and 
France (Appendix 1), and all centers that agreed to participate completed the survey. To 
demonstrate the number of children generally seen at these centers, their audit revealed that 
approximately 557 children per year with severe TBI are cared for at these centers. With 
respect to their goals for medical therapies routinely employed at these centers, there was 
some unanimity for the results of various thresholds for cerebrohemodynamics. All centers 
report that they use an ICP threshold of 20 mm Hg for the majority of subjects. Eight of the 
centers (25%) report that they use slightly lower ICP thresholds for the youngest children 
(10 mm Hg at one site, 15 mm Hg at four centers, and 18 mm Hg at three centers). For 
cerebral perfusion pressure (CPP), one site does not target CPP thresholds, whereas all 
others report use of a minimum CPP threshold. Three centers (9.4%) use a single CPP 
threshold (one site at 70 mm Hg, the other two at 60 mm Hg) for all subjects admitted with 
severe TBI. Nine centers report two different thresholds for subjects based on age, whereas 
the others report at least three different age-related thresholds. The lowest CPP threshold 
from any site was 35 mm Hg, whereas the highest was 75 mm Hg.
For intracranial hypertension therapies, CSF diversion was stratified into continuous 
drainage, intermittent drainage, or no drainage and a wide variety of strategies were 
identified (Table 3). For hyperosmolar therapies, one center does not use hypertonic saline 
while three do not use mannitol. The concentrations of hypertonic saline solutions used 
within centers are also striking, with one center reporting use of six different concentrations 
of such agents. In addition, three centers use the highest commercially available saline 
concentration of 23.4% saline. In four centers, only bolus doses of hypertonic saline 
solutions are used, whereas others use both boluses and continuous infusions. For hypoxia/
ischemia prevention and detection, none of the centers report intentionally using 
hyperventilation during periods of normal ICP. Ten centers (31.3%) monitor partial pressure 
of interstitial brain oxygen (Pbo2) with threshold values ranging from 20 to 35 mm Hg. For 
metabolic support, the distributions regarding timing of nutritional support and glucose 
administration are seen in Figures 1 and 2, respectively. For nutritional support, the most 
common time to start nutritional support was 48 hours after TBI, but the distribution varied 
widely. Within centers, there was significant variability in this goal as well (as indicated by 
the bars on the figure), starting from within the first 24 hours to starting from 48 to 96 hours 
after TBI. As for choices of nutritional support, 20 centers routinely use enteral feedings, 
eight parenteral prescriptions, and four use a combination of both. For glucose, the 
distribution of timing of administration is also variable, but earlier than for the start of 
nutritional support (Fig. 2). Interestingly, one site provides glucose only when the patient 
becomes hypoglycemic, one site administers glucose on an “age-dependent” basis, and one 
site begins glucose administration when ICP is less than 20 mm Hg. Nineteen centers 
(59.4%) use insulin regularly to control hyperglycemia, of which 10 use a locally derived 
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standard protocol for its administration. Thirteen centers do not use insulin regularly to 
control hyperglycemia after TBI.
DISCUSSION
We report that the medical goals, as derived from the self-described usual practices at 
centers that care for hundreds of children with severe TBI each year, vary greatly between 
institutions within our international consortium. This variability appears to be most 
prominent in areas where the literature is the least conclusive, including CSF diversion, 
metabolic goals, and Pbo2 monitoring. For topics with more evidence—hyperosmolar 
therapy and perhaps hyperventilation—there was a more unified approach to the medical 
goals. One comparable survey of these medical goals was performed by Segal et al (12) 
more than a decade ago. In this U.K. survey, they found that all centers practiced 
hyperventilation and mannitol use, whereas a subset of centers used furosemide, 
corticosteroids, fluid restriction, barbiturates, and hypothermia. Although the specific 
therapies in question were different than ours, this likely reflects the changes in TBI practice 
as new evidence has emerged over the past decade. Intriguingly, the ICP and CPP goals 
adopted by these institutions were quite similar to the ones that we observed. More recently, 
a survey of 194 U.S. clinicians found that approximately 60% of recommendations made 
within the contemporary guidelines (13) were part of their clinical goals. These results were 
similar to ours in that age-dependent ICP and CPP goals were reported and approximately 
36% of respondents did not use CSF diversion. However, the use of hyperosmolar therapies 
was significantly less than in our survey (57% for mannitol and 68% for hypertonic saline). 
Other efforts to understand medical decision making in pediatric TBI have used data 
collected from either databases or retrospective registries, generally concentrating on 
decisions for placement of ICP monitors (14, 15) or prospective studies discerning variations 
in practices between centers (16). Our survey is unique in outlining the variables that a large 
number of international institutions use as a part of their usual practice in children with 
severe TBI in three specific categories— intracranial hypertension therapies, hypoxia/
ischemia detection and prevention, and metabolic support—that have significant 
implications for outcomes and clinical trials.
Intracranial Hypertension Therapies
The decision regarding CSF diversion is quite unique, in that a clinician must decide 
whether or not to drain CSF in all cases. This binary question arises because ICP monitoring 
technology necessarily involves an externalized ventricular drain (which drains CSF) or a 
strain-gauge monitor within the parenchymal space (with cannot drain CSF). Currently, no 
studies are of sufficient quality to demonstrate the superiority of any CSF diversion strategy. 
The best evidence supporting CSF diversion is derived from a series of 23 children with 
refractory ICP—of which 20 children achieved control of intracranial hypertension with 
CSF diversion (17). Conversely, the evidence for the use of hyperosmolar therapies for 
intracranial hypertension is among the strongest for any topic within the guidelines. Based 
on two small RCTs (18, 19), the utility of hypertonic saline solutions to lower ICPs 
generated a level II recommendation that hypertonic saline “should” be considered. 
Although similar studies have not shown beneficial effects of mannitol, it has been used for 
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decades for treatment of intracranial hypertension (20). Our findings reflect these 
differences in level of evidence. There was wide disparity in CSF diversion goals between 
the various centers—and even within clinicians within centers themselves. This is quite 
consistent with the lack of conclusive evidence of the effectiveness of CSF drainage within 
the literature—as proponents may argue for its therapeutic potential and others may be 
concerned with complications of device placement. On the other hand, our study 
demonstrated wide adoption of hyperosmolar therapies, with only a few centers opting to 
not use either mannitol or hypertonic saline solutions. The variability we observed in this 
aspect of TBI care was focused more on the wide variety of concentrations of hypertonic 
saline solutions which was surprising.
Hypoxia/Ischemia Prevention and Detection
Hyperventilation—which lowers ICP by lowering cerebral blood flow and thereby cerebral 
blood volume in regions with intact Co2 reactivity—has been among the more controversial 
topics in pediatric neurotrauma care. Although a common practice in older studies, Skippen 
et al (21) demonstrated a significant decrease of cerebral blood flow with incremental 
decreases in Paco2, and other studies suggested that hypocarbia may be associated with 
unfavorable outcome (22). In our survey, centers reported that they did not intentionally use 
hyperventilation during periods of normal ICP, but it is likely to be a goal that the centers 
strive to achieve. In the Hyp-HIT study, more than 40% of subjects in the study were 
severely hyperventilated to PaCo2 less than 30 mm Hg (9). For Pbo2 monitoring of cerebral 
hypoxia, a number of reports have been published describing the utility of this system in 
children investigations have emerged in the past several years. Figaji et al (23, 24) have 
published several series describing the integration of Pbo2 into the neuromonitoring milieu 
of children with severe TBI, and it appears that a threshold of Pbo2 may be possible to 
determine in a large series. Our survey reflects the adoption of this technique by several 
centers, but the penetration of use for this technology is still limited—likely reflecting the 
relatively small amount of information currently available.
Metabolic Support
Although believed to be extremely important for wound healing, growth, and providing 
energy for physiologic/pathological processes, evidence for providing metabolic support for 
children with severe TBI is still rudimentary. Within the guidelines, only a single RCT of 40 
children who were fed an immune-enhanced diet was sufficiently rigorous to be included, 
and this study demonstrated that this diet was not associated with any meaningful outcomes 
(25). In adult TBI victims, the timing of nutritional support appears to play a role in 
outcomes (26). Specifically, in an audit of 797 adult TBI victims from New York State, 
those patients who did not get fed until the fifth or seventh day after trauma had a 2.4-fold 
and four-fold increase in mortality, respectively. Data from our survey suggest that the 
pediatric neurotrauma community is cognizant of this association, as most centers have the 
goal of starting nutritional support within the first several days after TBI. As for glucose, the 
data are similarly nebulous. Although several series have found that hyperglycemia is 
associated with adverse outcome in both the acute and more delayed time periods after TBI 
(27–29), there is little evidence to guide the clinician on when glucose administration should 
start and how hyperglycemia should be managed. This is reflected by the data from our 
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survey, where the range of time for starting glucose administration and insulin usage is quite 
wide across centers.
Limitations and Implications
There are several limitations to this study. First, this survey was performed in a relatively 
small number of centers in the United States, United Kingdom, and Europe and the results 
may not reflect the pediatric neurotrauma community as a whole. However, the purpose of 
this survey was to determine the variations that currently exist in a number of important 
treatments that are standardly applied for children, and the centers within this study treat 
more than 500 such children each year. Second, the respondents stated that the answers they 
gave were reflective of the overall care of children at their center. Obviously, actual 
practices at centers might deviate significantly from the stated goals— either because patient 
care dictates that a given goal could not be achieved or based on variability of care provided 
by clinicians at the centers. Lastly, this survey cannot address which goals are associated 
with the best outcomes for patients—an obvious goal for any future study. We believe that a 
prospective, observational, and cohort study with sufficient statistical power and detailed 
data collection could inform the pediatric neurotrauma community on the relative effects of 
these strategies on patient outcomes.
In conclusion, clinicians reported marked differences in medical goals for children with 
severe TBI across our international consortium. We believe that our data have significant 
implications. First, we speculate that there are superior strategies to achieve the medical 
goals outlined within our survey and believe that a study such as the one outlined above may 
yield important advances for the field. Second, given our data, it is conceivable that the 
widespread variability in clinical goals across institutions would yield marked variations in 
patient outcomes at the various centers. This may explain, in part, the failure of 
multicentered RCTs—as the effect of variability in medical therapies outlined in our survey 
may lead to variations in outcomes that obscure observable treatment effects of experimental 
interventions. We believe that future studies that determine the superiority of the various 
medical therapies outlined within our survey would be a significant advance for the pediatric 
neurotrauma field.
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Laura Loftis, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX; 
Kevin Morris, Birmingham Children’s Hospital, Birmingham, UK; Kerri LaRovere, Boston 
Children’s Hospital and Harvard University, Cambridge, MA; Philippe Meyer, Centre 
Hospitalier Universitaire Necker Enfantes Malades, Paris, France; Karen Walson, Children’s 
Healthcare of Atlanta, Atlanta, GA; Jennifer Exo, Children’s Hospital of Colorado, Denver, 
CO; Ajit Sarnaik, Children’s Hospital of Michigan and Wayne State University, Detroit, MI; 
Todd Kilbaugh, Children’s Hospital of Philadelphia, Philadelphia, PA; Darryl Miles, 
Children’s Medical Center, Dallas, TX; Mark Wainwright, Children’s Memorial Hospital, 
Chicago, IL; Nathan Dean, Children’s National Medical Center, Washington, DC; Ranjit 
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Chima, Cincinnati Children’s Hospital, Cincinnati, OH; Katherine Biagas, Columbia 
University Medical Center and the Children’s Hospital of New York Presbyterian, New 
York, NY; Mark Peters, Great Ormond Street Hospital and University College Hospital, 
London, UK; Joan Balcells and Joan Sanchez del Toledo, Hospital Vall d’Hebron, 
Barcelona, Spain; Courtney Robertson, Johns Hospital University, Baltimore, MD; Dwight 
Bailey, Lauren Piper and William Tsai, Levine Children’s Hospital of Carolinas Medical 
Center, Charlotte, NC; John Ragheb, Miami Children’s Hospital and University of Miami 
Miller School of Medicine, Miami, FL; Rachel Agbeko, Newcastle Upon Tyne Hospitals 
NHS Trust, Newcastle Upon Tyne, UK; Nicole O’Brien, Nationwide Children’s Hospital 
and Ohio State University, Columbus, OH; Amber Young, North Bristol NHS Trust, Bristol, 
UK; Neal Thomas, Pennsylvania State University, Hershey, PA; Sandra Buttram, Phoenix 
Children’s Hospital, Phoenix, AZ; Santiago Borasino, University of Alabama, Birmingham, 
AL; JoAnne Natale, University of California, Davis, Sacramento, CA; Christopher Giza, 
University of California, Los Angeles, CA; David Shellington, University of California, San 
Diego, CA; Deborah Stein, University of Maryland and R Adams Cowley Shock Trauma 
Center, Baltimore, MD; Robert Clark and Alicia Au, University of Pittsburgh, Pittsburgh, 
PA; Jerry Zimmerman, University of Washington, Seattle, WA; Jose Pineda, University of 
Washington, St. Louis, MO; and Peter Ferrazzano, University of Wisconsin, Madison, WI.
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Figure 1. 
Summary of the goals for starting of nutritional support from an international pediatric 
neurotrauma consortium consisting of 32 centers from the United States and Europe. Centers 
were asked, “When do you start nutritional support to patients?” and were able to respond in 
freeform text. Centers responded with discrete time points (“X” in the figure) or by 
describing a range of time periods where nutritional support was intended to be started 
(“line” in the figure). All times are expressed as time after traumatic brain injury (TBI).
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Figure 2. 
Summary of the goals for starting of glucose from an international pediatric neurotrauma 
consortium consisting of 32 centers from the United States and Europe. Centers were asked, 
“When do you start to administer glucose to patients?” and were able to respond in freeform 
text. Centers responded with discrete time points (“X” in the figure) or by describing a range 
of time periods where nutritional support was intended to be started (“line” in the figure). 
Three centers responded with goals that were not time-based (when intracranial pressure < 
20, when hypoglycemic, based on the age of patient) and are excluded from this figure. All 
times are expressed as time after traumatic brain injury (TBI).
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Table 1
Summary of Evidence and Recommendations Generated From the 2012 Pediatric Traumatic Brain Injury 
Guidelines (26)
Topic
Level of
Evidence Recommendation
Indications for ICP monitoring Level III “Use of ICP monitoring may be considered…”
Threshold for treatment of 
intracranial hypertension
Level III “Treatment of ICP may be considered at a threshold of 20 mm Hg”
Cerebral perfusion pressure 
thresholds
Level III “A minimum CPP of 40 mm Hg may be considered… A CPP threshold of 40–50 mm Hg 
may be considered…”
Advanced neuromonitoring Level III “If brain oxygenation monitoring is used, maintenance of Pbo2 ≥ 10 mm Hg may be 
considered”
Neuroimaging Level III “In the absence of neurological deterioration…routine repeat CT scan…may not be 
indicated…”
Hyperosmolar therapy Level II
Level III
“Hypertonic saline should be considered…for intracranial hypertension…effective doses…
range between 6.5 and 10 mL/kg”
“Hypertonic saline may be considered…effective doses as a continuous infusion of 3% 
saline range between 0.1 and 1.0 mL/kg/hr administered on a sliding scale…”
Temperature control Level II
Level III
“Moderate hypothermia…for only 24 hr duration should be avoided….moderate 
hypothermia starting within 8 hr after injury and lasting for 48 hr duration should be 
considered to reduce ICP…rewarming at a rate of 0.5°C/hr should be avoided”
“Moderate hypothermia…for 48 hr duration may be considered.”
Cerebrospinal fluid drainage Level III “Cerebrospinal fluid drainage through an externalized ventricular drain…may be 
considered…The addition of a lumbar drain may be considered…”
Barbiturates Level III “High-dose barbiturate therapy may be considered in hemodynamically stable patients with 
refractory intracranial hypertension….continuous arterial blood pressure monitoring and 
cardiovascular support to maintain adequate CPP are required”
Decompressive craniectomy for 
the treatment of intracranial 
hypertension
Level III “Decompressive craniectomy with duraplasty…may be considered for pediatric 
patients….showing early signs of neurological deterioration or herniation or are developing 
intracranial hypertension refractory to medical management…”
Hyperventilation Level III “Avoidance of prophylactic severe hyperventilation to a Paco2 < 30 mm Hg may be 
considered within the first 48 hr…If hyperventilation is used…advanced neuromonitoring 
for evaluation of cerebral ischemia may be considered”
Corticosteroids Level II “The use of corticosteroids is not recommended to improve outcome or lower ICP…”
Glucose and nutrition Level II
Level III
“The evidence does not support the use of an immune-modulating diet…to improve 
outcome”
“…glycemic control…should be left to the treating physician”
Antiseizure prophylaxis Level III “Prophylactic treatment with phenytoin may be considered to reduce the prevalence of early 
posttraumatic seizures…”
ICP = intracranial pressure (levels of evidence based on current traumatic brain injury guidelines with levels I–III [“must be considered,” “should 
be considered,” and “may be considered,” respectively]), CPP = cerebral perfusion pressure (mean arterial blood pressure minus mean ICP), Pbo2 
= partial pressure of interstitial brain oxygen.
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Table 2
Survey Questions
General
Audit of eligible patients over the past 3 yr
What is the ICP threshold routinely used in your institution?
Is the ICP threshold age-related? If so, how?
What is the CPP threshold routinely used in your institution?
Is the CPP threshold age-related? If so, how?
Intracranial hypertension therapies
  CSF diversion Do you use CSF diversion (via an externalized ventricular drain) in children with severe TBI?
If you use CSF diversion, do you drain CSF continuously or intermittently?
If you drain CSF intermittently, do you have a goal amount of CSF to drain or a goal ICP that you will 
drain CSF to achieve?
  Hyperosmolar therapies Do you use mannitol, hypertonic saline solutions, or both during intracranial hypertension crises?
If you use hypertonic saline solutions, what concentration(s) do you use?
If you use hypertonic saline solutions, do you use it as a bolus administration or as a continuous infusion 
or both?
Hypoxia/ischemia detection
  Hyperventilation Do you intentionally use hyperventilation during periods of normal ICP?
  Pbo2 monitoring Do you use Pbo2 monitoring in all children? If only a portion, approximately what percentage?
If you use Pbo2 monitoring, what is your Pbo2 target?
Metabolic support
  Nutritional support When do you start nutritional support to patients?
Do you use enteral nutrition, parenteral nutrition, or both?
  Glucose When do you start to administer glucose to patients?
Do you use insulin to control blood glucose? If so, do you use it by a defined protocol or by the bedside 
clinician’s judgment?
ICP = intracranial pressure, CPP = cerebral perfusion pressure (mean arterial blood pressure minus mean ICP), CSF = cerebrospinal fluid, Pbo2 = 
partial pressure of interstitial brain oxygen.
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Table 3
Summary of Cerebrospinal Fluid Diversion Strategies and Hyperosmolar Therapies
CSF Diversion Strategies n of 32 (% [95% CI])
Never use CSF diversion 11 (34.4% [18.6–53.2])
Intermittent CSF diversion only 0 (0% [0–10.9])
Continuous CSF diversion only 11 (34.4% [18.6–53.2])
Combinations
  No CSF diversion + continuous CSF diversion 2 (6.3% [0.8–20.8])
  No CSF diversion + intermittent CSF diversion 2 (6.3% [0.8–20.8])
  Intermittent CSF diversion + continuous CSF diversion 6 (18.8% [7.2–36.4])
Hyperosmolar therapy strategies
  Never use mannitol 3 (9.4% [2.0–25.0])
  Never use hypertonic saline solutions 1 (3.1% [0.1–16.2])
Concentrations of hypertonic saline solutions
  Only use one concentration 22 (68.8% [50–83.9])
    3% only 18
    2.7% only 2
    6.4% only 1
    7.4% only 1
  Use more than one concentration 10 (31.3% [16.1–50.0])
CSF = cerebrospinal fluid.
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